Foreign gene transfer to cardiomyocyte using a replication-defective recombinant coxsackievirus B3 without cytotoxicity

Intervirology

Volumn 55, Issue 3, 2012, Pages 201-209

  Lim, Byung Kwan ^a   Yun, Soo Hyeon ^a   Gil, Chae Ok ^a   Ju, Eun Seon ^a   Choi, Jin Oh ^a   Kim, Duk Kyung ^a   Jeon, Eun Seok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cardiac myocytes; Cardiotropic virus; Cytotoxicity; Replication defective recombinant coxsackievirus; Transfer vector

Indexed keywords

COMPLEMENTARY DNA; LUCIFERASE; RECOMBINANT DNA; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN HEK293; CONTROLLED STUDY; COXSACKIE VIRUS B; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DNA TRANSFECTION; ENZYME ASSAY; GENE AMPLIFICATION; GENE TARGETING; GENE TRANSFER; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NEWBORN; NONHUMAN; PLASMID; PRIORITY JOURNAL; RAT; VIRUS REPLICATION;

ANIMALS; CELLS, CULTURED; ENTEROVIRUS B, HUMAN; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HUMANS; LUCIFERASES; MICE; MYOCYTES, CARDIAC; TRANSDUCTION, GENETIC;

COXSACKIEVIRUS;

EID: 84857914224     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000324541     Document Type: Article

References (20)

1. Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU: Low-level expression of a mutant coxsackieviral CDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 1998; 98: 450-457. (Pubitemid 28357948)
2. Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, Kandolf R, Knowlton KU: Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitationcontraction coupling and dilated cardiomyopathy. J Clin Invest 1998; 102: 1444-1453. (Pubitemid 28467573)
3. Yu SF, Benton P, Bovee M, Sessions J, Lloyd RE: Defective RNA replication by poliovirus mutants deficient in 2a protease cleavage activity. J Virol 1995; 69: 247-252. (Pubitemid 24378800)
4. Lim BK, Shin JO, Lee SC, Kim DK, Choi DJ, Choe SC, Knowlton KU, Jeon ES: Long-term cardiac gene expression using a coxsackieviral vector. J Mol Cell Cardiol 2005; 38: 745-751. (Pubitemid 40591739)
5. Wessely R, Klingel K, Knowlton KU, Kandolf R: Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 2001; 103: 756-761. (Pubitemid 32144207)
6. Henke A, Nestler M, Strunze S, Saluz HP, Hortschansky P, Menzel B, Martin U, Zell R, Stelzner A, Munder T: The apoptotic capability of coxsackievirus B3 is influenced by the efficient interaction between the capsid protein VP2 and the proapoptotic host protein Siva. Virology 2001; 289: 15-22. (Pubitemid 33016233)
7. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S: A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious CDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996; 70: 7811-7818. (Pubitemid 26339087)
8. Porter DC, Ansardi DC, Choi WS, Morrow CD: Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection. J Virol 1993; 67: 3712-3719. (Pubitemid 23180691)
9. Porter DC, Ansardi DC, Morrow CD: Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 Gag gene by using a complementation system which provides the P1 capsid protein in trans. J Virol 1995; 69: 1548-1555.
10. Porter DC, Ansardi DC, Wang J, McPherson S, Moldoveanu Z, Morrow CD: Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology 1998; 243: 1-11. (Pubitemid 28384165)
11. Ansardi DC, Porter DC, Morrow CD: Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans. J Virol 1993; 67: 3684-3690. (Pubitemid 23143757)
12. Ansardi DC, Moldoveanu Z, Porter DC, Walker DE, Conry RM, LoBuglio AF, McPherson S, Morrow CD: Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res 1994; 54: 6359-6364.
13. Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, Baltimore D, Feinberg MB: Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 1994; 265: 1448-1451. (Pubitemid 24306798)
14. Meyer RG, Meyer-Ficca ML, Kaiser H, Selinka HC, Kandolf R, Kupper JH: Plasmidbased generation of recombinant coxsackievirus B3 particles carrying capsid gene replacement replicons. Virus Res 2004; 104: 17-26. (Pubitemid 38721260)
15. Cunningham KA, Chapman NM, Carson SD: Caspase-3 activation and ERK phosphorylation during CVB3 infection of cells: influence of the coxsackievirus and adenovirus receptor and engineered variants. Virus Res 2003; 92: 179-186. (Pubitemid 36398463)
16. Oie E, Vinge LE, Tonnessen T, Grogaard HK, Kjekshus H, Christensen G, Smiseth OA, Attramadal H: Transient, isopeptide-specific induction of myocardial endothelin-1 MRNA in congestive heart failure in rats. Am J Physiol 1997; 273:H1727-H1736.
17. Hofling K, Tracy S, Chapman N, Kim KS, Smith Leser J: Expression of an antigenic adenovirus epitope in a group B coxsackievirus. J Virol 2000; 74: 4570-4578. (Pubitemid 30237882)
18. Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL: Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 2001; 75: 2377-2387. (Pubitemid 32147576)
19. Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL: Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 2002; 76: 4430-4440. (Pubitemid 34309580)
20. Van Houten N, Bouchard PE, Moraska A, Huber SA: Selection of an attenuated coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen. J Virol 1991; 65: 1286-1290.